Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC
Authors
Keywords
-
Journal
MOLECULAR DIVERSITY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-31
DOI
10.1007/s11030-020-10036-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- hCES1 and hCES2 mediated activation of epalrestat-antioxidant mutual prodrugs: Unwinding the hydrolytic mechanism using in silico approaches
- (2019) Shalki Choudhary et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models
- (2019) Ryohei Katayama et al. Nature Communications
- Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
- (2019) Alice T Shaw et al. LANCET ONCOLOGY
- Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization
- (2018) Peter P. Luk et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET
- (2018) Pankaj Kumar Singh et al. BIOORGANIC CHEMISTRY
- Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey
- (2018) Antonin Levy et al. EUROPEAN JOURNAL OF CANCER
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations
- (2017) Xiaoyun Wu et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Chemotherapeutics-resistance “arms” race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer
- (2017) Pankaj Kumar Singh et al. LIFE SCIENCES
- Kinases inhibitors in lung cancer: From benchside to bedside
- (2016) Pankaj Kumar Singh et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis
- (2016) Disha Pathak et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy
- (2016) Zhengbo Song et al. Cancer Medicine
- PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
- (2015) Helen Y. Zou et al. CANCER CELL
- PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
- (2015) Helen Y. Zou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
- (2014) R. Katayama et al. CLINICAL CANCER RESEARCH
- Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set
- (2014) Huiyong Sun et al. PHYSICAL CHEMISTRY CHEMICAL PHYSICS
- P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape
- (2014) Huiyong Sun et al. PLoS Computational Biology
- Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments
- (2013) G. Madhavi Sastry et al. JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
- Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm
- (2013) Heounjeong Go et al. Journal of Thoracic Oncology
- Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
- (2013) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins
- (2013) M. A. Davare et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
- (2012) Kristin Bergethon et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting Fragment Binding Poses Using a Combined MCSS MM-GBSA Approach
- (2011) Muhammad K. Haider et al. Journal of Chemical Information and Modeling
- Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MM-GBSA calculation
- (2011) Juan Du et al. JOURNAL OF COMPUTATIONAL CHEMISTRY
- Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free Energy Perturbation and the OPLS Force Field
- (2010) Devleena Shivakumar et al. Journal of Chemical Theory and Computation
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation